Refine your search
Collections
Co-Authors
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Anoop Narayanan, V.
- Regulatory Approval Process for Drugs in Canada-A Challenging Task
Abstract Views :378 |
PDF Views:0
Authors
Affiliations
1 Department of Pharmaceutical Regulatory Affairs, NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Paneer, Deralakatte, Mangaluru-575018, Karnataka, IN
1 Department of Pharmaceutical Regulatory Affairs, NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Paneer, Deralakatte, Mangaluru-575018, Karnataka, IN
Source
Research Journal of Pharmacy and Technology, Vol 12, No 7 (2019), Pagination: 3206-3210Abstract
The drugs and medical devices for human use in Canada are regulated by Health Canada’s Therapeutic Products Directorate (TPD). Health Canada is responsible to implement the rules and regulations for the marketing of drugs. Health Canada’s process for approving new drugs is very slow and they give approval for drug products based on a complete review of safety and efficacy data. In Canada, around 70% of the new drugs were submitted over three months, and 40% more than one year, after their first submission. For drugs that were eventually approved to be marketed in Canada and in at least one of the other jurisdictions, the average delay from the first submission in either foreign jurisdiction to submission in Canada was 540 days. A drug approval process is completed by various applications submitted to the authority and the registration of drugs in Canada is really challenging. The purpose of this article is to provide information about the procedure from pre-submission to the marketing of a pharmaceutical drug for obtaining the drug approval in Canada.Keywords
Health Canada, ANDS, CTA, HPFB, NDS.
References
- Ali Shajarizadeh MA, Aiden Hollis. Delays in the submission of new drugs in Canada. CMAJ. 187(1), Jan 2015:47-51.
- Canada H, Products H, Branch F, Products Directorate T. mands_gespd-eng.pdf.[cited 2018 May 02]. Available from: https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/dhpmps/alt_formats/pdf/prodpharma/applic-demande/guide-ld/mgmt-gest/mands_gespd-eng.pdf.
- Distribution and marketing of drugs in Canada: Overview. [cited 26 April 2018]. Available from:https://content.next.westlaw.com/Document/Iffa811f25ac111e598dc8b09b4f043e0/View/FullText.html?contextData=(sc.Default) & transition Type=Default & first Page = true & bhcp=1
- DSM Sinochem Pharmaceuticals. Drug products. [cited 27 April 2018]. Available from: http://www.dsm-sinochem.com/About-Us/Our-global-network/Drug-Products.
- Government of Canada HC. Description: Appendix 6c: Abbreviated New Drug Submission (ANDS) or Supplement to an Abbreviated New Drug Submission (SANDS). [cited 2018 May 01]. Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/compli-conform/noccg_accd-longdesc3-eng.php
- How drugs are reviewed in Canada. [cited 27 April 2018]. Available from:https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/fact-sheets/drugs-reviewed-canada.html.
- Lexchin J. Health Canada’s use of its priority review process for new drugs: A cohort study. BMJ Open 2015;5: e006816. doi:10.1136/bmjopen-2014- 006816. Available from: http://dx.doi.org/10.1136/
- Mulaje SS. Procedure for drug approval in different countries: A Review. J Drug Deliv Ther. 3(2); 2013:1–21.
- Preeti MS et.al. New drug approval procedure in different countries: A Review. Int J Chem Tech Res. 10(12), 2017:1-21.
- Regulating Pharmaceutical Drugs- Health Canada. [cited 2018 April 27]. Available from: http://www.oagbvg.gc.ca/internet/English/parl_oag_201111_04_e_35936.html.
- Richard YC, Goodwin SH. An overview of Canadian and U.S. Approaches to drug regulation and responses to post market adverse drug reactions. J Diabetes Sci Technol. 7(2); 2013: 313-320.
- Shakeel SM et.al. Comparison of regulatory requirements for generic drugs dossier submission in United states and Canada. Int J Pharm Sci and Health care. 6(6); 2016: 1-19.